Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to 0.3.

  • Seres Therapeutics' Equity Ratio rose 12759.62% to 0.3 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.3, marking a year-over-year increase of 12759.62%. This contributed to the annual value of 0.1 for FY2024, which is 17881.82% up from last year.
  • As of Q3 2025, Seres Therapeutics' Equity Ratio stood at 0.3, which was up 12759.62% from 0.23 recorded in Q2 2025.
  • Seres Therapeutics' Equity Ratio's 5-year high stood at 0.47 during Q1 2021, with a 5-year trough of 0.27 in Q2 2024.
  • In the last 5 years, Seres Therapeutics' Equity Ratio had a median value of 0.13 in 2024 and averaged 0.14.
  • Within the past 5 years, the most significant YoY rise in Seres Therapeutics' Equity Ratio was 42536.51% (2024), while the steepest drop was 58636.02% (2024).
  • Quarter analysis of 5 years shows Seres Therapeutics' Equity Ratio stood at 0.37 in 2021, then tumbled by 91.66% to 0.03 in 2022, then crashed by 504.6% to 0.13 in 2023, then skyrocketed by 178.82% to 0.1 in 2024, then soared by 208.92% to 0.3 in 2025.
  • Its last three reported values are 0.3 in Q3 2025, 0.23 for Q2 2025, and 0.31 during Q1 2025.